Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Holders of 5% or more of TRDA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Entrada Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| 5AM Ventures V, L.P. | 13D/A | 10.80%4.12M shares | – | Nov 18, 20251 filing | Nov 18, 2025 | SEC |
| MPM BioVentures 2014, L.P. | 13D/A | 9.90%3.89M shares | – | Sep 10, 20261 filing | Sep 10, 2026 | SEC |
| Roche Finance Ltd | 13G/A | 6.90%2.57M shares | – | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.30%1.97M shares | New | Feb 4, 20251 filing | Feb 4, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
11 Schedule 13D and 13G filings on Entrada Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 20264:26 PM ET | MPM BioVentures 2014, L.P.and 12 others | 13D/A | 9.90%3.89M shares | – | Sep 8, 2026 | SEC |
| Aug 14, 20264:15 PM ET | TCG Crossover GP I, LLCand 2 others | 13G/A | 2.70%1.06M shares | −2.30 ppfrom 5.00%Below 5% | Jun 30, 2026 | SEC |
| Nov 25, 20254:29 PM ET | TCG Crossover GP I, LLCand 2 others | 13G | 5.00%1.92M shares | New | Nov 19, 2025 | SEC |
| Nov 18, 20254:38 PM ET | 5AM Ventures V, L.P.and 6 others | 13D/A | 10.80%4.12M shares | – | Nov 14, 2025 | SEC |
| Nov 14, 202512:19 PM ET | Price T Rowe Associates Inc | 13G/A | 0.90%360.5K shares | −5.90 ppfrom 6.80%Below 5% | Sep 30, 2025 | SEC |
| Aug 14, 20251:07 PM ET | Price T Rowe Associates Inc | 13G/A | 6.80%2.57M shares | – | Jun 30, 2025 | SEC |
| Aug 14, 202510:46 AM ET | Janus Henderson Group PLC | 13G/A | 4.00%1.52M shares | −1.60 ppfrom 5.60%Below 5% | Jun 30, 2025 | SEC |
| May 14, 202512:28 PM ET | Janus Henderson Group PLCand 1 other | 13G/A | 5.60%2.12M shares | 0.00 ppfrom 5.60% | Mar 31, 2025 | SEC |
| Feb 14, 20253:47 PM ET | Roche Finance Ltdand 1 other | 13G/A | 6.90%2.57M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 202511:25 AM ET | Janus Henderson Group PLCand 1 other | 13G | 5.60%2.08M shares | New | Dec 31, 2024 | SEC |
| Feb 4, 20253:45 PM ET | BlackRock, Inc. | 13G | 5.30%1.97M shares | New | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Entrada Therapeutics, Inc. shares.
No Form 144 notices for Entrada Therapeutics, Inc. are on file.